Revenue segments as reported by the company.

Grant revenue

Clinical trial revenue

Contract revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Research and development

Selling and marketing

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Longeveron

Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers on October 9, 2014 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Longeveron reports promising Q1 results, secures funding for growth

Longeveron's Q1 2024 earnings call highlighted positive Phase I results for HLHS and cost management efforts. The company secured funding for further development and welcomed new board members. Challenges include regulatory hurdles and market competition, but opportunities lie in expanding therapeutic applications and revenue growth potential.

Longeveron reports positive Q2 results, eyes contract services expansion

Longeveron's Q2 2024 earnings call highlighted strong performance in trials and financials, with a focus on HLHS program advancement and contract services expansion. The company faces challenges in addressing analyst inquiries and maximizing its contract services business potential, but has opportunities for revenue growth and leveraging positive trial outcomes.

Longeveron reports robust revenue growth and progresses towards FDA approval

Longeveron's Q3 2024 performance reflects strong revenue growth and advancements in regulatory pathways for their product candidate, Lomecel-B, across multiple therapeutic areas.
The company's focus on cellular therapies aligns with a lucrative market potential in the U.S., but funding needs for accelerated activities and competitive challenges pose considerations for future strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

BioMarin Pharmaceutical

BioNTech SE

Arcus Biosciences

Could these biotech stocks be poised for long-term gains?

4 Biotech Stocks To Watch This Week

Longeveron Inc (NASDAQ: LGVN) is a clinical biotech firm that develops cellular therapies to treat life-threatening and aging-related conditions. It announced that it had received approval from the FDA for the RPD (Rare Pediatric Disease) designation for its Lomecel-B to treat Hypoplastic Left Heart Syndrome.

Longeveron up 100% after FDA approves its Lomecel-B medical product

Biotechnology player Longeveron Inc. ( LGVN , Financial) more than doubled in value from a single trading session after a major U.S. FDA announcement. The clinical-stage biotech player, which is engaged in research and development using stem cell research to develop therapies to combat heart diseases, aging, frailty, Alzheimer's disease and other neurological disorders, recently received an encouraging update from the FDA in regards to one of its treatments, marking a key step on the path to profitability.

Why Did Longeveron's Stock Just Spike?

Express

Meten Holding Group Ltd.

Add these penny stocks to your November watchlist The post Do These Top Penny Stocks Have Upside Potential in November? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Do These Top Penny Stocks Have Upside Potential in November?

Today, the FDA has smiled on Longeveron, with investors in LGVN stock seeing absolutely astronomical gains of more than 180% this morning. The post LGVN Stock Alert: The Huge FDA News Sending Longeveron to the Moon Today appeared first on InvestorPlace.

LGVN Stock Alert: The Huge FDA News Sending Longeveron to the Moon Today

Shares of Longeveron Inc. LGVN, +126.38% blasted 120.9% higher on very active morning trading Thursday, after the biotechnology company said its Lomecel-B for the treatment of a congenital heart defect in infants (Hypoplastic Left Heart Syndrome) affecting about 1,000 babies a year was granted rare pediatric disease (RPD) designation by the Food and Drug Administration. Trading volume exploded to 112.0 million shares, compared with the full-day average of about 110,000 shares.

Longeveron stock rockets on very heavy volume after upbeat FDA news

The FDA has granted Rare Pediatric Disease (RPD) designation for Longeveron Inc's (NASDAQ: LGVN) Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS). HLHS is a rare and life-threatening congenital heart defect in infants.

Why Are Longeveron Shares Skyrocketing On Thursday?

Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per year Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per year

U.S. Food and Drug Administration Approves Longeveron's Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition

Longeveron Inc. (LGVN) CEO Geoff Green on Q3 2021 Results - Earnings Call Transcript

Longeveron to hold conference call today at 8:30 AM EST Longeveron to hold conference call today at 8:30 AM EST

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Los Angeles, California--(Newsfile Corp. - November 10, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ: LGVN) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on February 12, 2021 (the "IPO"), or between February 12, 2021 and August 12, 2021, inclusive (the...

DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - November 10, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or...

Last Days to Actively Participate in Longeveron Inc. (LGVN) Class Action - Bronstein, Gewirtz & Grossman, LLC

Los Angeles, California--(Newsfile Corp. - November 9, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ: LGVN) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on February 12, 2021 (the "IPO"), or between February 12, 2021 and August 12, 2021, inclusive (the...

FRIDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ: LGVN) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on February 12, 2021 (the "IPO"), or between February 12, 2021 and August 12, 2021, inclusive (the...

FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its third quarter 2021 financial results on Friday, November 12, 2021 before the open of US markets. Management will host a conference call on the same day at 8:30 a.m. ET.

Longeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021

New York, New York--(Newsfile Corp. - November 7, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers. The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 21-cv-23303, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline - LGVN

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company's initial public offering conducted on or about February 12, 2021 (the “IPO” or “Offering”); and/or (2) between February 12, 2021 and August 12, 2021, both dates inclusive (the “Class Period”), of the important November 12, 2021 lead plaintiff deadli

ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN

Los Angeles, California--(Newsfile Corp. - November 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ: LGVN) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on February 12, 2021 (the "IPO"), or between February 12, 2021 and August 12, 2021, inclusive (the...

7-DAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired: (a) Longeveron Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or ab

Last Few Days to Actively Participate in Longeveron Inc. (LGVN) Class Action - Bronstein, Gewirtz & Grossman, LLC

MIAMI, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (“Biorasi”) as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer's Disease (AD) subjects.

Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer's Disease Trial

Los Angeles, California--(Newsfile Corp. - November 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ: LGVN) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on February 12, 2021 (the "IPO"), or between February 12, 2021 and August 12, 2021, inclusive (the...

APPROACHING DEADLINE REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Longeveron Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

SAN DIEGO--(BUSINESS WIRE)---- $LGVN #LomecelB--Longeveron Inc. (LGVN) Materially Misrepresented the Viability of its Lead Product Lomecel-B

SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Longeveron Inc. (LGVN)

New York, New York--(Newsfile Corp. - October 31, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company's initial public offering conducted on or about February 12, 2021 (the "IPO" or "Offering"); and/or (2) between February 12, 2021 and August 12, 2021, both dates inclusive (the "Class Period"),...

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVN

NEW YORK, Oct. 27, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company's initial public offering conducted on or about February 12, 2021 (the "IPO" or "Offering"); and/or (2) between February 12, 2021 and August 12, 2021, both dates inclusive (the "Class Period"), of the important November 12, 2021 lead plaintiff deadline. SO WHAT: If you purchased Longeveron securities pursuant and/or traceable to the IPO and/or during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVN

New York, New York--(Newsfile Corp. - October 26, 2021) -  Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) from February 9, 2021 through August 12, 2021 (the "Class...

SHAREHOLDER ALERT- LONGEVERON INC. (LGVN) LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Longeveron Inc.

News for Longeveron Stock (LGVN)